291 related articles for article (PubMed ID: 32436460)
1. TNFα inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis.
Chen XY; Yan BX; Man XY
Ther Adv Respir Dis; 2020; 14():1753466620926800. PubMed ID: 32436460
[TBL] [Abstract][Full Text] [Related]
2. Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept.
Duret PM; Sebbag E; Mallick A; Gravier S; Spielmann L; Messer L
Ann Rheum Dis; 2020 Sep; 79(9):1251-1252. PubMed ID: 32354772
[No Abstract] [Full Text] [Related]
3. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
4. May IL-17 have a role in COVID-19 infection?
Megna M; Napolitano M; Fabbrocini G
Med Hypotheses; 2020 Jul; 140():109749. PubMed ID: 32339777
[No Abstract] [Full Text] [Related]
5. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.
Ye Q; Wang B; Mao J
J Infect; 2020 Jun; 80(6):607-613. PubMed ID: 32283152
[TBL] [Abstract][Full Text] [Related]
6. The role of Interleukin 6 inhibitors in therapy of severe COVID-19.
Nasonov E; Samsonov M
Biomed Pharmacother; 2020 Nov; 131():110698. PubMed ID: 32920514
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 revisiting inflammatory pathways of arthritis.
Schett G; Manger B; Simon D; Caporali R
Nat Rev Rheumatol; 2020 Aug; 16(8):465-470. PubMed ID: 32561873
[TBL] [Abstract][Full Text] [Related]
8. Proposed use of thalidomide for the cytokine storm of COVID-19.
Goihman-Yahr M
Clin Dermatol; 2020; 38(4):508. PubMed ID: 32972614
[No Abstract] [Full Text] [Related]
9. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
[TBL] [Abstract][Full Text] [Related]
10. Dapsone and doxycycline could be potential treatment modalities for COVID-19.
Farouk A; Salman S
Med Hypotheses; 2020 Jul; 140():109768. PubMed ID: 32339778
[No Abstract] [Full Text] [Related]
11. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
Almerie MQ; Kerrigan DD
Med Hypotheses; 2020 Oct; 143():109883. PubMed ID: 32492562
[TBL] [Abstract][Full Text] [Related]
12. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.
Zhang C; Wu Z; Li JW; Zhao H; Wang GQ
Int J Antimicrob Agents; 2020 May; 55(5):105954. PubMed ID: 32234467
[TBL] [Abstract][Full Text] [Related]
13. Immune-Mediated Coagulopathy in COVID-19 Infection.
Vadasz Z; Brenner B; Toubi E
Semin Thromb Hemost; 2020 Oct; 46(7):838-840. PubMed ID: 32877959
[No Abstract] [Full Text] [Related]
14. Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.
Smetana K; Brábek J
In Vivo; 2020 Jun; 34(3 Suppl):1589-1592. PubMed ID: 32503815
[TBL] [Abstract][Full Text] [Related]
15. Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.
Hoiland RL; Stukas S; Cooper J; Thiara S; Chen LYC; Biggs CM; Hay K; Lee AYY; Shojania K; Abdulla A; Wellington CL; Sekhon MS
Br J Haematol; 2020 Aug; 190(3):e150-e154. PubMed ID: 32584416
[No Abstract] [Full Text] [Related]
16. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.
Wu D; Yang XO
J Microbiol Immunol Infect; 2020 Jun; 53(3):368-370. PubMed ID: 32205092
[TBL] [Abstract][Full Text] [Related]
17. The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response.
Arnaldez FI; O'Day SJ; Drake CG; Fox BA; Fu B; Urba WJ; Montesarchio V; Weber JS; Wei H; Wigginton JM; Ascierto PA
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385146
[TBL] [Abstract][Full Text] [Related]
18. [SARS-CoV-2 infection in a patient treated by hydroxychloroquine and anti TNF α for Inflammatory Rheumatic Disease].
Malek SA; Bouchti IE
Pan Afr Med J; 2020; 35(Suppl 2):134. PubMed ID: 33193949
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab administration in a refractory case of COVID-19.
Dastan F; Nadji SA; Saffaei A; Tabarsi P
Int J Antimicrob Agents; 2020 Aug; 56(2):106043. PubMed ID: 32502524
[No Abstract] [Full Text] [Related]
20. Alternative management of Covid-19 infection.
Atrah HI
Scott Med J; 2020 Aug; 65(3):72-75. PubMed ID: 32638647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
